Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery
NCT07278661Phase 2Recruiting
- Sponsor
- CHU de Nantes
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of romiplostim in Thrombocytopenia (2 arms), sponsored by CHU de Nantes. Primary endpoint: Efficacy at 28 days. Started Jul 2026; status: recruiting.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT07278661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07278661.